Research objective
AVX-1 is the name of a research program, not a physical molecule. The program is intended to investigate whether an α2A positive allosteric modulator can strengthen the receptor’s response to endogenous norepinephrine without relying on continuous direct agonism.
Published preclinical evidence indicates that α2A autoreceptors participate in presynaptic inhibitory control of norepinephrine release. Aeviant interprets that regulatory role as a reason to test whether endogenous-signal dependence can provide a different form of control from an agonist acting through its own efficacy.
That interpretation is the program hypothesis, not an experimental finding. The literature and its limitations are reviewed on the α2A autoregulation page.
What the program must show
The core requirements are reproducible potentiation in the presence of endogenous norepinephrine, acceptably low intrinsic agonism, receptor-subtype selectivity and the intended Gi-biased, arrestin-sparing signalling profile.
Further work would need to establish tractable chemistry, coherent results across independent methods, appropriate tissue exposure and an acceptable cardiovascular, autonomic and overall safety profile.
AVX-1 advances only if those results support the intended pharmacology and justify the next stage. The program will be redirected or stopped if direct agonism dominates, ligand dependence or subtype selectivity fails, functional evidence contradicts the model, or the required exposure and therapeutic window are impractical.
Current work
The initial literature framework, computational target characterization and patent-pending public thesis are complete.
A computational campaign is underway to generate, challenge and prioritize molecular hypotheses. Its outputs remain predictions until tested experimentally.
The next material decision requires chemistry, synthesis and experimental pharmacology. Technical discussion beyond the public thesis requires a signed non-disclosure agreement.